Home » Stocks » Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc. (ARPO)

Stock Price: $1.26 USD -0.02 (-1.56%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 51.14M
Revenue (ttm) 2,144
Net Income (ttm) -18.70M
Shares Out 40.59M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $1.26
Previous Close $1.28
Change ($) -0.02
Change (%) -1.56%
Day's Open 1.27
Day's Range 1.24 - 1.29
Day's Volume 676,894
52-Week Range 0.42 - 1.53

More Stats

Market Cap 51.14M
Enterprise Value 16.68M
Earnings Date (est) Aug 18, 2020
Ex-Dividend Date n/a
Shares Outstanding 40.59M
Float 26.23M
EPS (basic) -0.46
EPS (diluted) -0.46
FCF / Share -0.46
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 83,456
Short Ratio 0.02
Short % of Float 0.39%
Beta 2.12
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 23,853.02
PB Ratio 1.54
Revenue 2,144
Operating Income -19.72M
Net Income -18.70M
Free Cash Flow -18.84M
Net Cash 34.46M
Net Cash / Share 0.85
Gross Margin n/a
Operating Margin -919,669.92%
Profit Margin n/a
FCF Margin -878,629.76%
ROA -24.59%
ROE -44.62%
ROIC 1,254.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 0
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

$1.50*
Low
1.50
Current: 1.26
High
1.50
Target: 1.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue-20.16---
Gross Profit-20.16---
Operating Income-24.44-11.18-21.39-16.63-0.02
Net Income-23.27-10.40-21.40-16.98-0.03
Shares Outstanding40.5933.9321.670.855.00
Earnings Per Share-0.57-0.31-1.03-24.52-0.01
Operating Cash Flow-23.85-5.81-18.88-15.72-0.02
Capital Expenditures-0.24-0.04-0.01-0.11-
Free Cash Flow-24.09-5.85-18.89-15.83-0.02
Cash & Equivalents38.5662.6520.291.680.02
Total Debt0.17--12.390.16
Net Cash / Debt38.3962.6520.29-10.71-0.14
Assets39.9464.1221.032.400.02
Liabilities3.405.463.5988.620.21
Book Value36.5458.6717.44-86.22-0.19
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aerpio Pharmaceuticals, Inc.
Country United States
Employees 12
CEO Joseph H. Gardner

Stock Information

Ticker Symbol ARPO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ARPO

Description

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds for the treatment of ocular diseases and diabetic complications. The company's lead product candidate is razuprotafib, a small molecule activator of the Tie2 pathway, which completed the Phase IIb clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is in a Phase 1b clinical trial for the treatment of inflammatory bowel disease; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a collaboration with Quantum Leap Healthcare Collaborative for the evaluation of razuprotafib in the treatment of acute respiratory distress syndrome in adult patients with moderate to severe COVID-19. The company is headquartered in Cincinnati, Ohio.